JP2024516217A5 - - Google Patents

Info

Publication number
JP2024516217A5
JP2024516217A5 JP2023565918A JP2023565918A JP2024516217A5 JP 2024516217 A5 JP2024516217 A5 JP 2024516217A5 JP 2023565918 A JP2023565918 A JP 2023565918A JP 2023565918 A JP2023565918 A JP 2023565918A JP 2024516217 A5 JP2024516217 A5 JP 2024516217A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
bonded
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516217A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/089737 external-priority patent/WO2022228497A1/zh
Publication of JP2024516217A publication Critical patent/JP2024516217A/ja
Publication of JP2024516217A5 publication Critical patent/JP2024516217A5/ja
Pending legal-status Critical Current

Links

JP2023565918A 2021-04-30 2022-04-28 腫瘍疾患の治療における医薬の使用 Pending JP2024516217A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110482012 2021-04-30
CN202110482012.2 2021-04-30
PCT/CN2022/089737 WO2022228497A1 (zh) 2021-04-30 2022-04-28 药物在治疗肿瘤疾病中的应用

Publications (2)

Publication Number Publication Date
JP2024516217A JP2024516217A (ja) 2024-04-12
JP2024516217A5 true JP2024516217A5 (cg-RX-API-DMAC10.html) 2025-05-02

Family

ID=83846722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565918A Pending JP2024516217A (ja) 2021-04-30 2022-04-28 腫瘍疾患の治療における医薬の使用

Country Status (15)

Country Link
US (1) US20240238434A1 (cg-RX-API-DMAC10.html)
EP (1) EP4331614A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516217A (cg-RX-API-DMAC10.html)
KR (1) KR20240004657A (cg-RX-API-DMAC10.html)
CN (2) CN121490094A (cg-RX-API-DMAC10.html)
AU (2) AU2022263701B2 (cg-RX-API-DMAC10.html)
BR (1) BR112023022540A2 (cg-RX-API-DMAC10.html)
CA (1) CA3217111A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023003211A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023014715A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23082749A (cg-RX-API-DMAC10.html)
GE (1) GEAP202416383A (cg-RX-API-DMAC10.html)
IL (1) IL308098A (cg-RX-API-DMAC10.html)
MX (1) MX2023012797A (cg-RX-API-DMAC10.html)
WO (1) WO2022228497A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024175042A1 (zh) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 药物偶联物治疗肿瘤疾病的用途及方法
JP2026517367A (ja) * 2023-05-22 2026-05-29 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド 腫瘍疾患の治療における薬物コンジュゲートの使用およびその方法
KR20260042361A (ko) * 2023-06-30 2026-03-31 머크 샤프 앤드 돔 엘엘씨 치료 조합물, 및 이의 용도 및 치료 방법
TW202539746A (zh) * 2024-04-03 2025-10-16 大陸商四川科倫博泰生物醫藥股份有限公司 偶聯物在治療腫瘤疾病中的用途及方法
TW202604574A (zh) * 2024-05-22 2026-02-01 大陸商四川科倫博泰生物醫藥股份有限公司 抗體藥物偶聯物在預防或治療疾病中的應用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144878A2 (en) * 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
RU2725292C2 (ru) * 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
JP2018058822A (ja) * 2016-08-03 2018-04-12 ファイザー・インク ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
EP3617221A4 (en) * 2017-04-19 2021-04-14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN110903395A (zh) * 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 抗体、偶联物及其制备方法和用途

Similar Documents

Publication Publication Date Title
US20250059201A1 (en) Camptothecin compound and conjugate thereof
JP2023539715A5 (cg-RX-API-DMAC10.html)
EP4217398B1 (en) Anti-c-met antibody drug conjugates
JP2022543780A5 (cg-RX-API-DMAC10.html)
JP2020509027A5 (cg-RX-API-DMAC10.html)
JP2018537975A5 (cg-RX-API-DMAC10.html)
JP2023545096A5 (cg-RX-API-DMAC10.html)
US20240091374A1 (en) Anti-sez6 antibody drug conjugates
AU2022263701B2 (en) Use of medicament in treatment of tumor disease
JP2021534188A5 (cg-RX-API-DMAC10.html)
CN115869325A (zh) 化合物用于制备治疗kras突变癌症患者的药物的用途
JP2024531353A5 (cg-RX-API-DMAC10.html)
WO2025103379A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2024175042A1 (zh) 药物偶联物治疗肿瘤疾病的用途及方法
JP2024519449A5 (cg-RX-API-DMAC10.html)
CN101291675B (zh) 抗癌组合药物
JP2024511977A5 (cg-RX-API-DMAC10.html)
WO2025247187A1 (zh) 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
JP2023531090A5 (cg-RX-API-DMAC10.html)
WO2025061110A1 (zh) 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途
JP2025503511A5 (cg-RX-API-DMAC10.html)
JP2023500385A5 (cg-RX-API-DMAC10.html)
HK40122430A (en) Method for treating cancer with anti-b7h3 antibody-drug conjugate
JP2025542384A5 (cg-RX-API-DMAC10.html)